BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 27114418)

  • 1. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.
    Lee K; Sinn DH; Gwak GY; Cho HC; Jung SH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Gut Liver; 2016 Sep; 10(5):796-802. PubMed ID: 27114418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
    Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
    J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy.
    Wu CK; Chang KC; Hung CH; Tseng PL; Lu SN; Chen CH; Wang JH; Lee CM; Tsai MC; Lin MT; Yen YH; Hu TH
    J Antimicrob Chemother; 2016 Jul; 71(7):1943-7. PubMed ID: 27073265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspartate Aminotransferase-to-Platelet Ratio or Fibros-4 Index Predicts the Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients with Sustained Virologic Response to Interferon Therapy.
    Na SK; Lee SJ; Cho YK; Kim YN; Choi EK; Song BC
    J Interferon Cytokine Res; 2019 Nov; 39(11):703-710. PubMed ID: 31216229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
    Tong MJ; Theodoro CF; Salvo RT
    J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.
    Toyoda H; Tada T; Tachi Y; Hirai T; Yasuda S; Honda T; Hayashi K; Ishigami M; Goto H; Kumada T
    Antivir Ther; 2017; 22(3):185-193. PubMed ID: 27586087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Post-treatment α-Fetoprotein Levels and Aspartate Aminotransferase-to-Platelet Ratio Index Predict Hepatocellular Carcinoma in Hepatitis C Virus Decompensated Cirrhotic Patients with Sustained Virological Response After Antiviral Therapy.
    Ji F; Zhou R; Wang W; Bai D; He C; Cai Z; Shen Y; Wang S; Deng H; Li Z
    J Interferon Cytokine Res; 2017 Aug; 37(8):362-368. PubMed ID: 28731786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
    Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia.
    Paik N; Sinn DH; Lee JH; Oh IS; Kim JH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Liver Int; 2018 Jan; 38(1):68-75. PubMed ID: 28581248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.
    Chen TM; Lin CC; Huang PT; Wen CF
    Tumour Biol; 2016 Jun; 37(6):7129-37. PubMed ID: 26662957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
    Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
    Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.
    Wang JH; Yen YH; Yao CC; Hung CH; Chen CH; Hu TH; Lee CM; Lu SN
    Liver Int; 2016 Dec; 36(12):1793-1799. PubMed ID: 27254286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents.
    Hsu WF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen HY; Wang HW; Huang GT; Peng CY
    BMC Gastroenterol; 2019 Apr; 19(1):63. PubMed ID: 31029101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Point System to Forecast Hepatocellular Carcinoma Risk Before and After Treatment Among Persons with Chronic Hepatitis C.
    Xing J; Spradling PR; Moorman AC; Holmberg SD; Teshale EH; Rupp LB; Gordon SC; Lu M; Boscarino JA; Schmidt MA; Trinacty CM; Xu F;
    Dig Dis Sci; 2017 Nov; 62(11):3221-3234. PubMed ID: 28965221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
    Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
    J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response.
    Sasaki R; Yamasaki K; Abiru S; Komori A; Nagaoka S; Saeki A; Hashimoto S; Bekki S; Kugiyama Y; Kuno A; Korenaga M; Togayachi A; Ocho M; Mizokami M; Narimatsu H; Ichikawa T; Nakao K; Yatsuhashi H
    PLoS One; 2015; 10(6):e0129053. PubMed ID: 26070204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
    Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
    J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.